Southern Illinois University School of Medicine Becomes Clinical Site for CVM Phase III Trial
CEL-SCI Corporation today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) has activated another U.S. clinical site at Southern Illinois University School of Medicine's Simmons Cancer Institute in Springfield, Illinois. The Illinois site, which has become part of the world's largest Phase III trial for head and neck cancer with dozens of hospitals and clinical centers in 12 countries, has now officially joined the study. According to the...
View full press release